Cardio-oncology Related to Heart Failure, An Issue of Heart Failure Clinics, 1st Edition
Authors :
Daniel J. Lenihan & Douglas B. Sawyer
As the number of effective anti-neoplastic agents has grown, there has been a concomitant increase in side effects. Cardiotoxicity, and specifically LV dysfunction, remains the limiting factor for many such agents, and is the focus of growing r ...view more
As the number of effective anti-neoplastic agents has grown, there has been a concomitant increase in side effects. Cardiotoxicity, and specifically LV dysfunction, remains the limiting factor for many such agents, and is the focus of growing research and clinical emphasis. This issue summarizes for the heart failure specialist the possible ways that chemotherapeutic agents might cause cardiotoxicity as well as the methods for detecting, treating and preventing cardiotoxicity.
As the number of effective anti-neoplastic agents has grown, there has been a concomitant increase in side effects. Cardiotoxicity, and specifically LV dysfunction, remains the limiting factor for many such agents, and is the focus of growing research and clinical emphasis. This issue summarizes for the heart failure specialist the possible ways that chemotherapeutic agents might cause cardiotoxicity as well as the methods for detecting, treating and preventing cardiotoxicity.
Author Information
By Daniel J. Lenihan, MD, FACC, Professor of Medicine, Director, Cardio-Oncology Center of Excellence, Advanced Heart Failure, Clinical Research, Cardiovascular Division, Washington University in St. Louis, St. Louis Missouri and Douglas B. Sawyer, M.D., Ph.D., FACC, Maine Medical Center Department of Cardiac Services Portland, ME, USA
https://www.us.elsevierhealth.com/cardio-oncology-related-to-heart-failure-an-issue-of-heart-failure-clinics-9781455711017.html6660Cardio-oncology Related to Heart Failure, An Issue of Heart Failure Clinicshttps://www.us.elsevierhealth.com/media/catalog/product/9/7/9781455711017.jpg69.2998.99USDInStock/Medicine/Cardiology/Clinics/Clinics464388725525504113841826925145120As the number of effective anti-neoplastic agents has grown, there has been a concomitant increase in side effects. Cardiotoxicity, and specifically LV dysfunction, remains the limiting factor for many such agents, and is the focus of growing research and clinical emphasis. This issue summarizes for the heart failure specialist the possible ways that chemotherapeutic agents might cause cardiotoxicity as well as the methods for detecting, treating and preventing cardiotoxicity. As the number of effective anti-neoplastic agents has grown, there has been a concomitant increase in side effects. Cardiotoxicity, and specifically LV dysfunction, remains the limiting factor for many such agents, and is the focus of growing research and clinical emphasis. This issue summarizes for the heart failure specialist the possible ways that chemotherapeutic agents might cause cardiotoxicity as well as the methods for detecting, treating and preventing cardiotoxicity.00add-to-cart97814557110172011 and earlierProfessionalBy Daniel J. Lenihan, MD, FACC and Douglas B. Sawyer, M.D., Ph.D., FACC20111Book178w x 254h (7.00" x 10.00")Saunders168Jul 27, 2011IN STOCK - This may take up to 5 business days to shipBy <STRONG>Daniel J. Lenihan</STRONG>, MD, FACC, Professor of Medicine, Director, Cardio-Oncology Center of Excellence, Advanced Heart Failure, Clinical Research, Cardiovascular Division, Washington University in St. Louis, St. Louis Missouri and <STRONG>Douglas B. Sawyer</STRONG>, M.D., Ph.D., FACC, Maine Medical Center Department of Cardiac Services Portland, ME, USAClinicsClinicsThe Clinics: Internal MedicineNoNoNoNoPlease SelectPlease SelectPlease Select
